Arm Holdings plc - American Depositary Shares (ARM)

Personal care market share gains and value-tier momentum show how the company is winning across consumer segments despite industry headwinds.

Church & Dwight’s third quarter results were driven by broad-based organic growth across its core product categories and a strong showing from its power bran...

Organic sales beat guidance at 5.1% as volume gains offset inflation.

Investors had to know this day was coming sooner or later.

Capital spending is accelerating, but retail margins are expanding simultaneously, a rare combination that tests whether Amazon can sustain profitability through its AI buildout.

Household products company Church & Dwight (NYSE:CHD) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 1% year on year to $...

CPUs still have a lot of growth potential even with weakness in PCs.

We can call it "The Intel Effect."

Church & Dwight (NYSE:CHD) reported third-quarter results that exceeded its prior outlook, led by volume growth, innovation and broad-based gains across its domestic, international and specialty products businesses. The company also raised its full-year organic sales outlook while tightening its

Zenas BioPharma (NASDAQ:ZBIO) outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of clinical data expected later in the quarter. Founder and Chief Executive Officer Lonnie Moulder sai

New stores are outperforming by $200,000 per location while sourcing gains protect margins, creating a dual growth engine.

The stock has struggled due to the bad housing market.

Palantir has rallied impressively in recent months, and its upcoming report could give the stock another boost.

It's starting to feel like this ticker might never stop falling.

SpaceX's growth is impressive, but its valuation leaves little room for disappointment.

Alphabet’s chip business is just starting to contribute to results.

How much of the Claude maker's rent goes to the chip giant?

Arm commands premium valuations on its licensing dominance, while Western Digital trades at a steep discount due to the industry's cyclical nature.

The banking giant is still pretty skeptical about Bitcoin.

Brazil stocks tumbled on election news, though not much is changing after the result.

The medication, which is being developed with the company's Chinese partner, did very well in a late-stage clinical trial.

Astrazeneca (NYSE:AZN) highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support the company’s oncology growth strategy. Dave Fredrickson, executive vice president of the company’s o

Xencor (NASDAQ:XNCR) reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026 conference. The company said it selected a 400 microgram-per-kilogram intravenous target dose for

Dogecoin Labs aims to make the world's first meme coin more useful.

The satellite business model lets Eni expand clean energy without straining core capital allocation.